KeyBioscience AG Report issue

For profit Phase 1 Phase 2
Founded: Nidwalden Switzerland (2017)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2017
NCT03230786
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

KeyBioscience AG